News
Article
Author(s):
The platform enables clinicians to tailor GLP-1 titration at scale, aiming to reduce discontinuation rates and improve long-term outcomes for patients undergoing obesity treatment.
Closed Loop Medicine, a biotech company developing combination prescription drug and software products, has unveiled WeDosify in the United States, which allows clinicians to personalize GLP-1 titration at scale.1
The solution is now commercially available to clinicians and patients.
As it stands, the global anti-obesity market was worth over $30 billion in 2024—projections anticipate it hitting $100 billion by the year 2030. However, this growth is a bit misleading, being that GLP-1 therapy adherence has been quite a challenge. Currently, data show that up 44% of patients discontinue treatment within six months, and those projections increase to 60% within one year.
It’s believed that this could potentially be due related to the gastrointestinal side effects that come with taking the recommended dosage, including diarrhea, nausea, and vomiting. It also could be argued that there isn’t enough information available regarding how these meds should be utilized in the longer term in order to keep the weight off.
WeDosify addresses these challenges by presenting individualized dosing options for clinical review, based on tolerability, treatment goals, and clinical data and adapting these over time based on the individual’s response to the drug. The platform enables healthcare providers, telehealth companies, and health systems to make informed titration decisions using the best available evidence, and maintain patients on effective therapy for longer.
Existing research has shown that patients who stop taking GLP-1 medications for weight loss tend to experience a rebound effect—the drugs are designed to promote weight loss via suppression of appetite. Once the user goes off the drug, their original hunger levels from often return to their normal levels, causing cases of over-eating.2
WeDosify pulls from 29 clinical studies and 15,000+ patient profiles, including various hypertension trials pointing to “better treatment outcomes, fewer side effects, and exceptional adherence.”
In fact, 91% of GLP-1 patients that were surveyed either “agreed” or “strongly agreed” with the sentiment that they were more likely remain adherent to treatment with the help of WeDosify.
“I am delighted to have the opportunity to share WeDosify with my patients,” said Susan Neese, MD, clinician in Texas. "It will enable me to work with each patient to determine a course of action that is genuinely personal to them, helping them to achieve lasting weight loss.”
The platform enables real-time simulations alongside patient and clinician reporting, supporting the White House’s HTI-4 initiative (short for health data, technology, and interoperability) that is intended to build a patient-centered digital healthcare ecosystem and harnessing digital tools to drive improved outcomes. Essentially, its goal is to streamline electronic health records.
“We are seeing an increasing number of companies trying to offer more personalized services to support patients on GLP-1 therapies, but the actual level of personalization is very limited and early results are showing little impact on overall patient discontinuations, noted Kate Woolland, CEO of Closed Loop Medicine.
“WeDosify is the first product that offers genuinely personalized recommendations which update in real time to reflect how the patient is responding to the drug. For the first time, patients can see what their weight loss journey might look like and work alongside their clinician to make decisions about their health. This is a genuine game-changer, and a crucial step in realizing our mission to make personalized care accessible to all.”
References
1. Closed Loop Medicine Launches First Personalized GLP-1 Dosing Platform in US. Closed Loop Medicine. September 18, 2025. Accessed September 22, 2025. https://www.closedloopmedicine.com/closed-loop-medicine-launches-first-personalized-glp1-dosing-plarform-in-the-usa/
2. Hollan M. Closed Loop Medicine Launches First Personalized GLP-1 Dosing Platform in US. Pharmaceutical Executive. September 4, 2025. Accessed September 22, 2025. https://www.pharmexec.com/view/everything-know-state-glp1-medications
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
